Evidence map›Paper›PMID 35172866›Full record

ReviewOrphanet journal of rare diseases2022

Challenges and improvement needs in the care of patients with central diabetes insipidus.

H Teare, J Argente, M Dattani, J Leger, M Maghnie, M Sherlock, G-C Ali, J Francombe, S Marjanovic

Abstract readReview
In one paragraph

Review in Orphanet journal of rare diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Arginine Vasopressin Deficiency and Oxytocin Deficiency in the Endocrine Clinic.The Journal of clinical endocrinology and metabolism · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

H TeareRAND Europe, Westbrook Centre Milton Road, Cambridge, CB4 1YG, UK.
J ArgenteDepartment of Pediatrics and Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús, Instituto de Investigación La Princesa, Universidad Autónoma de Madrid, Madrid, Spain.
M DattaniUCL Great Ormond Street (GOS) Institute of Child Health, University College London, London, UK.
J LegerAssistance Publique-Hôptaux de Paris, Pediatric Endocrinology-Diabetology Department, Reference Center for Growth and Development Endocrine Diseases, Robert Debré University Hospital, Université de Paris, NeuroDiderot INSERM UMR 1141, 75019, Paris, France.
M MaghnieDepartment of Pediatrics, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
M SherlockDepartment of Endocrinology, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland.
G-C AliRAND Europe, Westbrook Centre Milton Road, Cambridge, CB4 1YG, UK.
J FrancombeRAND Europe, Westbrook Centre Milton Road, Cambridge, CB4 1YG, UK.
S MarjanovicRAND Europe, Westbrook Centre Milton Road, Cambridge, CB4 1YG, UK. smarjano@randeurope.org.ORCID 0000-0002-6956-2007

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Central diabetes insipidus (CDI) is a rare condition, with significant impact on patient health and well-being. It is a chronic condition which usually requires meticulous long-term care. It can affect both children and adults. There is limited literature considering the needs and challenges inherent in providing high quality care to patients with CDI, across the care pathway. This paper seeks to address this gap by providing a unique and well-rounded understanding of clinical and healthcare systems-related challenges. It draws on insights from the literature, from direct clinical experience contributed by five clinicians as co-authors (providing insights from France, Ireland, Italy, Spain and the United Kingdom), and from patient perspectives provided through interviews with patient representatives from three patient organisations. We identify clinical challenges related to the diagnosis of CDI, including differentiating between other similar conditions and determining the underlying aetiology. Treatment is challenging, given the need to tailor medication to each patient's needs and ongoing management is required to ensure that patients continue to respond adequately to treatment. Ongoing support is required when patients switch between formulations. We also identify healthcare systems challenges related to limited awareness of CDI amongst primary care physicians and general paediatricians, and the need for highly skilled specialist care and appropriate workforce capacity. There is also a significant need for raising awareness and for the education of both healthcare professionals and patients about different aspects of CDI, with the aim of supporting improved care and effective patient engagement with healthcare professionals. We reflect on this information and highlight improvement opportunities. These relate to developing guidance to support patients, carers, primary care physicians and general paediatricians to identify clinical features earlier, and to consider CDI as a possible diagnosis when a patient presents with suggestive symptoms.

Indexed as

Diabetes Insipidus, NeurogenicDiabetes MellitusAdultChildDelivery of Health CareHealth PersonnelHumansQuality of Health CareSurveys and QuestionnairesCentral diabetes insipidusDDAVPDisease burdenHealthcare improvementHealthcare systemsRare disease

Identifiers

PMID35172866
PMCPMC8848805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.